Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Paola Toniati,Simone Piva,Marco Cattalini,Emirena Garrafa,Francesca Regola,Francesco Castelli,Franco Franceschini,Paolo Airò,Chiara Bazzani,Eva-Andrea Beindorf,Marialma Berlendis,Michela Bezzi,Nicola Bossini,Maurizio Castellano,Sergio Cattaneo,Ilaria Cavazzana,Giovanni-Battista Contessi,Massimo Crippa,Andrea Delbarba,Elena De Peri,Angela Faletti,Matteo Filippini,Matteo Filippini,Micol Frassi,Mario Gaggiotti,Roberto Gorla,Michael Lanspa,Silvia Lorenzotti,Rosa Marino,Roberto Maroldi,Marco Metra,Alberto Matteelli,Denise Modina,Giovanni Moioli,Giovanni Montani,Maria-Lorenza Muiesan,Silvia Odolini,Elena Peli,Silvia Pesenti,Maria-Chiara Pezzoli,Ilenia Pirola,Alessandro Pozzi,Alessandro Proto,Francesco-Antonio Rasulo,Giulia Renisi,Chiara Ricci,Damiano Rizzoni,Giuseppe Romanelli,Mara Rossi,Massimo Salvetti,Francesco Scolari,Liana Signorini,Marco Taglietti,Gabriele Tomasoni,Lina-Rachele Tomasoni,Fabio Turla,Alberto Valsecchi,Davide Zani,Francesco Zuccalà,Fiammetta Zunica,Emanuele Focà,Laura Andreoli,Nicola Latronico
DOI: https://doi.org/10.1016/j.autrev.2020.102568
IF: 17.39
2020-07-01
Autoimmunity Reviews
Abstract:A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia.A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8 mg/kg by two consecutive intravenous infusions 12 h apart. A third infusion was optional based on clinical response.The outcome measure was an improvement in ARDS assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24–72 h and 10 days after tocilizumab administration.Out of 100 treated patients (88 M, 12 F; median age: 62 years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0–2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS≥7 before TCZ). Overall at 10 days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died.All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and interleukin 6 (IL-6) indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10.In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement.